19:50 , Jun 17, 2019 |  BC Innovations  |  Distillery Therapeutics

Scorpion venom-derived benzoquinones could treat Staphylococcus and tuberculosis infections

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus, tuberculosis Two benzoquinone derivatives derived from scorpion venom could help treat Staphylococcus aureus and Mycobacterium tuberculosis infections. Bacterial growth assays showed the derivatives inhibited growth of an S. aureus...
00:14 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

BMP2- and lysostaphin-loaded hydrogel for bone repair, infection

DISEASE CATEGORY: Infectious disease; musculoskeletal INDICATION: Staphylococcus; bone repair Mouse studies suggest PEG-based hydrogel loaded with BMP2 and lysostaphin could help treat S. aureus infection due to implant contamination and help repair bone. The hydrogel,...
13:05 , Apr 25, 2019 |  BC Extra  |  Preclinical News

Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing. Samira Kiani, an ASU assistant professor who co-led the study, told...
17:10 , Apr 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Lanthipeptide-based antibiotics for Gram-positive bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Gram-positive bacterial infection; Staphylococcus; Enterococcus; Streptococcus Cell culture studies identified multiple lanthipeptide-based antibiotics that could help treat Gram-positive bacterial infections. Screening in cell-based growth assays of a library of compounds...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

The bacterial AgrA inhibitor apcidin for MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus Cell culture and mouse studies suggest the S. aureus AgrA inhibitor apcidin could help treat methicillin-resistant S. aureus (MRSA) infection. In four strains of S. aureus , the natural...
12:21 , Mar 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Pore-forming peptide for multiple bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia; Pseudomonas; Staphylococcus In silico and cell culture studies identified a pore-forming peptide that could help treat E. coli , Pseudomonas and Staphylococcus infections. Molecular dynamics simulations of polyleucine-based peptide...
21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus; Streptococcus; Gram-positive bacterial infection In vitro , cell culture, mouse, rat and dog studies identified a spiropyrimidinetrione-based bacterial DNA gyrase inhibitor that could help treat Staphylococcus , Streptococcus and other Gram-positive bacterial infections....
13:51 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus In vitro , cell culture and mouse studies identified three TNC-based fusion proteins against S. aureus leukocidin ED or S. aureus γ-hemolysin AB that could help prevent and treat Staphylococcus infections. Screening of...
17:35 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Contrafect to test S. aureus therapy in Phase III despite Phase II miss

Exebacase (CF-301) from ContraFect Corp. (NASDAQ:CFRX) plus standard of care (SOC) antibiotics missed the primary endpoint of improving clinical response rate at day 14 vs. SOC alone in a Phase II trial to treat Staphylococcus...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated phosphorylation of PLC1, which...